.png){kind=icon}
Return
Gene editing using large insertions
.png){kind=icon}
PRE
AI
DOI：10.1038/s41587-026-03319-6.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
While technologies for smaller gene edits, such as base editing, have already entered clinical trials, larger gene cargoes face different challenges, including low editing efficiencies, delivery vehicle size constraints, and possible immunogenicity. Programmable genome engineering systems using recombinases; transposases, including CRISPR-associated transposases (CASTs); genome writing systems; and retrotransposons promise different avenues for therapy, but each system has unique limitations. What are the most promising strategies to further develop these technologies, and which parameters need to be further improved to make them efficient and safe for therapy? We asked three experts in the field to share their thoughts on the challenges and opportunities.
Journal
IF:
41.7
Papers:
1.2W
Citations:
10.1W
Organization
No organization information available
Cited Papers
Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases.png)
NATURE BIOTECHNOLOGY
NATURE BIOTECHNOLOGYIF41.7
PREAI
ShareSaveONE-STEP tagging: a versatile method for rapid site-specific integration by simultaneous reagent deliveryNUCLEIC ACIDS RESEARCH
OAAI
NUCLEIC ACIDS RESEARCHIF13.1
OAAIShareSaveShareSave
Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipidsNATURE BIOTECHNOLOGY
NATURE BIOTECHNOLOGYIF41.7
PREAI
ShareSaveShareSaveShareSave no more
no more